We are a leading, clinically advanced biopharmaceutical stem cell company with more than 20 years of experience at our Heidelberg, Germany site, dedicated to drug development based on ABCB5-positive (ABCB5+) mesenchymal stem cells as a platform technology.

Our focus is on the development of innovative stem cell therapies for patients suffering from severe immune- and inflammation-related diseases with high unmet medical need – particularly in the field of rare diseases. Our goal is to establish new therapeutic standards where satisfactory treatment options have not yet been available.

Our ABCB5-positive adult mesenchymal stem/stromal cells derived from the skin represent a characterized, highly purified active pharmaceutical ingredient – protected by patents and manufactured according to the highest quality standards (GMP/GfP/GLP). In certain indications, they have the potential to be a true game changer and a turning point in therapy. As a manufacturer of Advanced Therapy Medicinal Products (ATMPs) in accordance with Section 13 of the German Medicines Act (AMG), we develop and produce proprietary cell therapeutics that are currently in late-stage clinical trials that are currently in late-stage clinical trials.

More than 110 employees contribute every day to bringing innovative cell therapies into clinical practice – perhaps you will soon be one of them?